NCT05431608View on ClinicalTrials.gov

A Study of MCARH109 and MCARH125 in People With Multiple Myeloma

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

June 20, 2022

Primary Completion Date

June 20, 2026

Study Completion Date

June 20, 2026

Conditions
Multiple MyelomaRefractory Multiple MyelomaRelapse Multiple Myeloma
Interventions
BIOLOGICAL

MCARH125

MCARH109 and MCARH125 will be administered 2-7 days following the completion of conditioning chemotherapy. Each dose cohort will consist of 3-6 patients. MCARH109 and MCARH125 will be administered sequentially with 5-30 minutes between the two products.

BIOLOGICAL

MCARH109

MCARH109 and MCARH125 will be administered 2-7 days following the completion of conditioning chemotherapy. Each dose cohort will consist of 3-6 patients. MCARH109 and MCARH125 will be administered sequentially with 5-30 minutes between the two products.

Trial Locations (7)

10065

Memorial Sloan Kettering Cancer Center, New York

10604

Memorial Sloan Kettering Westchester (Limited protocol activities), Harrison

11553

Memorial Sloan Kettering Nassau (Limited protocol activities), Uniondale

11725

Memorial Sloan Kettering Commack (Limited protocol activities), Commack

07920

Memorial Sloan Kettering Basking Ridge (Limited protocol activities), Basking Ridge

07748

Memorial Sloan Kettering Monmouth (Limited protocol activities), Middletown

07645

Memorial Sloan Kettering Bergen (Limited protocol activities), Montvale

All Listed Sponsors
lead

Memorial Sloan Kettering Cancer Center

OTHER